See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/232698308

Overflow Microfluidic Networks: Application to the Biochemical Analysis of Brain Cell Interactions in Complex Neuroinflammatory Scenarios

ARTICLE in ANALYTICAL CHEMISTRY · OCTOBER 2012

Impact Factor: 5.64 · DOI: 10.1021/ac302094z · Source: PubMed

CITATIONS

4

READS

31

8 AUTHORS, INCLUDING:



Fabio Bianco

Sanipedia srl

28 PUBLICATIONS 866 CITATIONS

SEE PROFILE



Ana Ruiz

European Commission

51 PUBLICATIONS 1,097 CITATIONS

SEE PROFILE



Michela Matteoli

University of Milan

138 PUBLICATIONS 7,839 CITATIONS

SEE PROFILE



pubs.acs.org/ac

1 Overflow Microfluidic Networks: Application to the Biochemical ² Analysis of Brain Cell Interactions in Complex Neuroinflammatory 3 Scenarios

- ⁴ Fabio Bianco,*,^{†,¶} Noemi Tonna,^{†,¶} Robert D. Lovchik,[‡] Rosa Mastrangelo,[†] Raffaella Morini,^{§,||}
 ⁵ Ana Ruiz,^{§,||} Emmanuel Delamarche,[‡] and Michela Matteoli^{||,⊥}
- 6 [†]Neuro-Zone s.r.l., viale Ortles 22/4, 20139 Milano, Italy
- 7 [‡]IBM Research GmbH, Säumerstrasse 4, 8803 Rüschlikon, Switzerland
- §Fondazione Filarete, viale Ortles 22/4, 20139 Milano, Italy
- Department of Medical Biotechnology and Translational Medicine, University of Milano, Milano, Italy
- ¹Humanitas Clinical and Research Center, Rozzano, Italy

11

12

13

15

16

17

18

19

20

21 22

23

24

25


26

27

28

29

ABSTRACT: Neuroinflammation plays a central role in neurodegenerative diseases and involves a large number of interactions between different brain cell types. Unraveling the complexity of cell-cell interaction in neuroinflammation is crucial for both clarifying the molecular mechanisms involved and increasing efficacy in drug development. Here, we provide a versatile analytical method for specifically addressing cell-tocell communication, using primary brain cells, a microfluidic device, and a multiparametric readout approach. Different cell types are plated in separate chambers of a microfluidic network



so that culturing conditions can be independently controlled and single cell types can be selectively primed with different stimuli. When chambers are microfluidically connected, the specific contribution of each cell type can be finely monitored by analyzing morphology, vitality, calcium dynamics, and electrophysiology parameters. We exemplify this approach by examining the role of astrocytes derived from two different brain regions (cortex and hippocampus) on neuronal viability in two types of neuroinflammatory insults, namely, metabolic stress and exposure to amyloid β fibrils, and demonstrate regional differences in glial control of neuronal physiopathology. In particular, we show that during metabolic stress, cortical but not hippocampal astrocytes play a neuroprotective role; also, in an exacerbated inflammatory scenario consisting in the exposure to $A\beta + IL-1\beta$, hippocampal but not cortical astrocytes play a detrimental role on neurons. Aside from bringing novel insights into the glial role in neuroinflammation, the method presented here represents a promising tool for addressing a wide range of biological and biochemical phenomena, characterized by a complex interaction of multiple cell types.

Teuroinflammation is a nonspecific immune reaction to tissue damage, neurodegeneration, or pathogen invasion, 33 which occurs via the combined action of resident cells such as 34 microglia and astrocytes and systemic cells like monocytes and 35 macrophages.1 It is widely established that the inflammatory 36 response promoted by tissue damage serves to further engage 37 the immune system, thus initiating tissue repair. Whereas in 38 most cases this response is self-limiting and induces beneficial 39 effects (e.g., phagocytosis of debris and apoptotic cells), 40 sustained inflammation may result in tissue pathology, favoring 41 the production of neurotoxic factors that amplify underlying 42 disease states. In the latter case, the sustained inflammatory 43 responses that contribute to neurodegeneration, although 44 initially triggered in a disease-specific manner, may end up in 45 becoming independent of the original inflammation-inducing 46 molecules, such as amyloid- β (A β) in the case of Alzheimer's 47 disease or metabolic alteration in the case of ischemia.²

Activation of astrocytes and microglia—the latter being the 49 resident immune cells in the CNS—is one of the universal

components of neuroinflammation, and crosstalk among these 50 cells activate positive feedback loops, which may result in the 51 amplification of inflammation. A large effort is therefore 52 required to understand the cell-to-cell biochemical interactions 53 underlying the neuroprotective or neurotoxic roles of microglia 54 and astrocytes and how these interactions are perturbed in 55 chronic disease states.3

Given the large number of possible combinatorial 57 interactions between different brain cell types contributing to 58 inflammations, and since cellular responses can be modulated 59 by spatial and temporal signals from the surroundings, 4,5 there 60 is a critical need for the identification of new strategies enabling 61 cell-to-cell interactions to be addressed while manipulating 62 cellular microenvironments. Microtechnology has provided 63 tools to create microdevices for conducting many types of 64

Received: July 24, 2012 Accepted: October 24, 2012






Figure 1. Illustration of an oMFN having two cell chambers, functional analysis of the cells in the chambers, and protocols for probing cells interactions. (a) Cell cultures can be grown independently, each with its own culturing medium, on the vicinal cell chambers of a oMFN made in PDMS. The oMFN can subsequently be closed using a lid at the appropriate culturing time. The wettable microstructures around the chambers wick away excess culture medium, guaranteeing perfect sealing and avoiding mixing of liquids. The six ports glued on the lid are in regard with microchannels servicing the chambers and can be left open, closed with a threaded plug, or connected to a computer-controlled syringe. For example, injecting a solution via port 2 while leaving port 4 open and the other ports closed results in perfusing both chambers one after the other. (b) Before closing the oMFN with a lid, cells can be extensively monitored as shown in these representative images of HNs grown on oMFNs. Cells differentiate in culture and express late-stage specific markers (i.e., Vglut), and staining with β III tubulin shows development of the neuronal network. Moreover, representative traces of mEPSCs on HNs grown either under standard culturing conditions on glass or on oMFNs are shown. These traces exhibit comparable amplitude and frequency (see text for details). (c) Table and sketch showing experimental combinations for culturing and stimulating different cell populations plated in the chambers.

65 laboratory assays on a very small scale with cost and time 66 savings and fine control of experimental setups. In particular, 67 microfluidics have recently been used to study cellular 68 ensembles as well as single cells. 6,7 Advantages of microfluidics 69 over larger cell culture systems include the fact that few cells 70 can be seeded, cultured, and studied in defined chemical and 71 topographical environments.^{8,9} However, most microfluidic 72 devices lack flexibility, require complex protocols for cell 73 deposition and maintenance in vitro, and do not allow a 74 simultaneous analysis of morphological and real-time functional 75 parameters. For example, microfluidics having multiple 76 compartments for studying neurons and neuritic insults have 77 been developed but it is difficult to keep one compartment 78 independently stimulated from the other because the compart-79 ments are isolated by carefully maintaining an appropriate 80 hydrostatic pressure between them. 10 In another example, a 81 hand-held recirculation system was developed for culturing and

imaging cells. This system includes many functionalities for 82 seeding cells, pumping, and cell perfusion, but each cell culture 83 requires one device and set of peripherals.¹¹ Here, we use 84 overflow microfluidic networks (oMFNs)¹² for investigating 85 various stress conditions on primary neurons, either in isolation 86 or in microfluidic biochemical communication with glial cells. 87 oMFNs have open cell chambers that are surrounded with array 88 of wettable micropillars (i.e., "overflow zones"). These 89 microfluidic chips therefore permit depositing and culturing 90 cells for days and afterward closing the chambers with a lid for 91 circulating precise amounts of chemicals/solutions throughout 92 the chambers (see below). The general concept of seeding cells 93 and studying them in open or closed chambers using 94 microfluidics is broadly pursued. 13-15 Here, we specifically 95 combine microfluidic-based experiments (i.e., culture and 96 stimulation/stress of cells) with characterization methods 97 such as immunocytochemical staining, quantitative intracellular 98




Figure 2. Effect of hippocampal (HAs) and cortical (CAs) astrocytes on neuronal viability during ischemic insult. (a) Representation of the experiments in which hippocampal neurons (HNs), grown independently or in microfluidic communication with either CAs or HAs, are challenged with oxygen—glucose deprivation (OGD) protocol. (b) Representative vitality images showing DAPI (blue)/PI (red) staining of HNs, grown either independently (protocols 1 and 2) or in microfluidic communication with either HAs (protocol 3) or CAs (protocol 4) and challenged with the OGD protocol. (c) Percentage of cell death following OGD protocol. Whereas challenged HAs and CAs do not exhibit increased cell death, challenged HNs show about 20% cell death. This number is significantly lower in OGD experiments that had HNs in microfluidic communication with CAs.

99 calcium imaging, and electrophysiological recordings, thus 100 achieving a new method for efficiently dissecting specific cell 101 type contribution. In addition, oMFNs are simple and 102 disposable elements, which can be used with standard 103 equipment such as cell incubators, syringe-based pumps, and 104 inverted microscopes. Through this novel approach, we 105 demonstrate that astrocytes from distinct brain regions 106 differentially affect hippocampal neurons (HNs) challenged 107 with different types of inflammatory stimuli.

08 RESULTS

Device Concept. The oMFNs used for all experiments 109 110 presented here are made in poly(dimethylsiloxane) (PDMS). 111 The oMFNs have a footprint of 32 × 26 mm², and the small 112 separation distance of 1.6 mm between the chambers (edge-to-113 edge distance) allows visualization of both chambers simultaneously using a 4x microscope objective. The layout of the 115 channels and corresponding ports permit liquids to be drawn 116 sequentially or independently, if needed, through the chambers. The oMFNs are briefly treated with an oxygen-based plasma and coated with poly-L-lysine before a cell suspension is placed on each cell chamber. The overflow zones around the cell chambers have numerous wettable microstructures, which withdraw any excess liquid during the closing of the chip and ensure a sealing of the cells chambers. Figure 1a shows that different liquid droplets deposited on each cell chamber do not 124 mix when the chip is closed. After sealing the oMFN with a Si 125 lid, six ports are available for establishing specific culture or 126 stimulating conditions by pumping media through the 127 chambers with well-defined flow rates for the required time. 128 For example, ports 1, 2, and 5 can be used to flush liquids 129 through chamber A sequentially or in parallel so as to create a 130 biochemical gradient in this chamber. 16 For flushing a chemical

in both chambers, port 2 can be used while keeping ports 1, 3, $_{131}$ 5, and 6 closed and port 4 open. The volume of each chamber $_{132}$ is approximately 0.5 μ L, thus minimizing the amount of cells $_{133}$ required. Moreover, by using high-precision pumps with flow $_{134}$ rates ranging from 10 to 50 nL s $^{-1}$ very small amounts of $_{135}$ reagents or culture media can be drawn through the cell $_{136}$ chambers.

For the experiments described in this study, primary HNs 138 from E18 rat embryos were seeded in a cell chamber and 139 cultured for up to 10 days in vitro (DIV) before seeding 140 primary astrocytes from P2 pups in the other chamber. Cell- 141 containing oMFNs can be placed in an incubator, and the 142 medium can conveniently be exchanged by pipetting as much 143 and often as required before performing experiments. Figure 1b 144 shows the different combinations of distinct cell populations 145 plated in the chambers, the cell chamber connectivity, and the 146 modalities of cell stimulation used in the present study. Cells 147 can be grown in chambers either separately (II) or while being 148 in microfluidic communication (\leftrightarrow) . One cell population can 149 be separately challenged with specific stimuli for a desired 150 duration while the other cell population is kept perfused with 151 culture medium (i.e., AsllBc) and then put into microfluidic 152 communication for the required experimental time (i.e., As↔ 153 Bc). Alternatively, cells can be challenged while in microfluidic 154 communication, thus enabling analysis of functional effects 155 produced by soluble factors and/or organelles released from 156 cells cultured in chamber A on target cells in chamber B. Target 157 cells can be regularly inspected and assessed in terms of 158 morphological/functional properties using standard optical, 159 fluorescence, and electrophysiological characterization meth- 160

Functional Properties of Neurons Grown on oMFNs 162 or in Standard Cultures. Primary HNs plated on oMFNs 163




Figure 3. Role of hippocampal (HAs) and cortical (CAs) astrocytes on neuronal viability in the context of $A\beta$ insult. (a) Protocols involved HNs that were cocultured with either CAs or HAs, previously primed with $A\beta$ or with $A\beta$ + IL-1 β . (b) Representative vitality images showing DAPI (blue)/PI (red) and β III tubulin (green) staining of HNs from the four protocols described in panel a. (c) Comparison of death rates of HNs (unlabeled bar). HNs in microfluidic communication with HAs show a significant increase of cell death. This is not observable when HNs are cocultured with CAs. The detrimental effect, which primed HAs have on HNs, seems to relate to glutamate excitotoxicity because the presence of APV significantly reduces cell death.

164 develop normally and form wide networks of cells connected by 165 synaptic contacts, as revealed by immunocytochemical staining with β III tubulin (Figure 1b). The ability of neurons plated on oMFN to form synaptic contacts (sites of communication 168 among neurons) is demonstrated by immunocytochemical 169 staining for the synaptic vesicle glutamate transporter vGlut, 170 which labels presynaptic boutons (Figure 1b, arrowheads). Quantitative evaluation of intracellular calcium concentrations 172 shows basal intracellular calcium levels comparable to neurons 173 maintained under standard culturing conditions on poly-L-174 lysine-coated glass (F340/380; glass, 0.69 + 0.04; PDMS, 0.56 0.03; n = 20, p = 0.35, Student's t test) and a similar 176 amplitude of the peak response following exposure to depolarizing stimuli with 50 mM KCl (F340/380; glass, 0.14 177 0.01; PDMS, 0.15 + 0.01; cells number = 15, three 179 independent experiments, Student's t test). Furthermore, HNs grown on glass or oMFNs show comparable amplitude (pA; 181 glass, 92.67 + 10.01; PDMS, 105.97 + 15.45; cells number = 10, three independent experiments, p = 0.26, Student's t test) and 183 frequency (Hz; glass, 2.74 + 0.58; PDMS, 2.41 + 0.73; cells number = 10, three independent experiments, p = 0.97, Student's t test) of miniature excitatory postsynaptic currents (mEPSCs) recorded using whole-cell patch-clamp. These data 187 indicate that primary neuronal cultures from rat hippocampus 188 grown on oMFNs exhibit morphological, functional, and 189 electrophysiological properties similar to those of neurons 190 grown in standard culturing conditions on glass coverslips;

hence, growth of cultures in the cell chambers of the chip 191 neither influences neuronal viability nor the overall cellular 192 phenotype and development.

Hippocampal or Cortical Astrocytes Differently 194 Protect Hippocampal Neurons during Ischemic Insult. 195 We interrogated the contribution of specific cell types to 196 neuroinflammatory events that lead to neuronal degeneration 197 in a well-characterized in vitro model of ischemia, namely, 198 oxygen-glucose deprivation (OGD) protocol. ¹⁷ To this end, 199 primary HNs were grown in chamber B, while either cortical 200 (CA) or hippocampal (HA) astrocytes were grown in chamber 201 A (Figure 2a). Cells were either cultured independently (Figure 202 f2 2a, protocols 1 and 2) or kept in microfluidic communication 203 (Figure 2a, protocols 3 and 4) in open microfluidic setting. 204 Within these protocols, cells in the different oMFN chips were 205 maintained either in standard culturing conditions (Ac, Bc) or 206 challenged with the OGD protocol (As, Bs). After 2 h of OGD, 207 cells were allowed to recover for 24 h before being subjected to 208 viability assays. The quantitative evaluation of cell viability, 209 expressed as ratio of propidium iodide (PI) positive cells to the 210 total number of cells (Figure 2b, nuclear DAPI staining, blue; 211 PI, red) revealed that, whereas astrocytes (HA, CA) remain 212 largely viable after the OGD challenge (PI/DAPI%: CA = 0.60 213 + 0.12%; HA = 2.24 + 0.77%), neurons (HN) maintained in 214 isolation display a significant percentage of PI positive cells 215 (19.18 + 4.65%, p < 0.01, Figure 2c). Notably, OGD challenge 216 of HNs maintained in microfluidic communication with CAs 217




Figure 4. (a) Representation of the experiments in which hippocampal (HAs, protocol 1) and cortical (CAs, protocol 2) astrocytes are primed with $A\beta + IL-1\beta$ and then either further cultured independently (upper panel) or immediately put into microfluidic communication with HNs (lower panel). (b) Two representative traces showing single-cell ratiometric calcium acquisitions of HNs in chamber B exposed to glial-conditioned medium from chamber A coming either from independent culturing (upper panel) or immediate microfluidic communication (lower panel) (PPh = postpriming medium from HAs; PPc = postpriming medium from CAs; CMh = coculture medium from HAs; CMc = coculture medium from CAs). (c) Quantification of either cell calcium influx in HNs following exposure to glial-conditioned medium either from HAs (PPh) or CAs (PPc) with respect to biochemical depolarization by exposure to 50 mM KCl (upper panel) and quantification of basal intracellular calcium levels in HNs cultured either independently or in microfluidic communication with either HAs (1) or CAs (2) primed with $A\beta + IL-1\beta$ (lower panel).

218 results in a significant reduction of PI positive cells (2.90 + 219 2.08%, cells number = 30, three independent experiments, p < 220 0.01) with respect to neurons maintained in microfluidic 221 communication with HAs (19.58 + 3.80%, cells number = 30, 222 three independent experiments p = 0.95, analysis of variance 223 (ANOVA), post hoc Tukey's method), suggesting a neuro-224 protective role played by CAs, but not by HAs.

Hippocampal or Cortical Astrocytes Differently Affect 225 226 Neuronal Viability during Aβ Insult. To address whether 227 the different effect on the neuronal viability exerted by 228 astrocytes derived from different brain regions is limited to 229 conditions of ischemic insult, we employed oMFNs to dissect 230 cell-specific contributions in another neuroinflammatory context, namely, the exposure of brain cells to amyloid β fibrils. HNs were grown in chamber B, while either CAs or HAs 233 were grown in chamber A (Figure 3a) in open microfluidic 234 setting. CAs and HAs in chamber A were independently exposed during 24 h to either A β alone or to A β + the proinflammatory cytokine IL-1 β (Figure 3a), washed, and put 237 into closed microfluidic communication for 6 h with HNs (chamber B). HAs, CAs, and HNs independently challenged with either $A\beta$ or $A\beta$ + IL-1 β do not show significant cell death 240 (HN = 2.65 + 1.72; HA = 6.71 + 1.33; CA = 5.97 + 1.12; cells 241 number = 15, three independent experiments, post hoc 242 Tukey's method). Also, HNs, put into closed microfluidic 243 communication for 6 h with CAs and HAs, previously primed 244 only with $A\beta$ or IL-1 β , show only a moderate increase in 245 neuronal death (data not shown), thus confirming the previously reported observation that IL-1 β or $A\beta$ fibrils alone 246 do not heavily impact neuronal viability. However, when HNs 247 were put into closed microfluidic communication with HAs 248 previously challenged with $A\beta$ + IL-1 β , a significant increase in 249 cell death was detected (Figure 3b, HN = 16.20 + 2.44; cells 250 number = 15; three independent experiments, p < 0.01, post 251 hoc Dunnett's method), which was not observed in HNs 252 cocultured with CAs under the same conditions (Figure 3c, HN 253 = 6.48 + 1.47; cells number = 15; three independent 254 experiments, p = 0.35, post hoc Tukey's method). The harmful 255 effect of HAs on HNs following exposure to $A\beta$ + IL-1 β was 256 abolished in the presence of APV, a selective antagonist of 257 NMDA receptors (Figure 3c).

To address whether HN damage may result from the release 259 of soluble mediators by HAs when exposed to $A\beta$ + IL-1 β , we 260 took advantage of the possibility to close the oMFN lid and 261 flush the cells in chamber B with the medium from chamber A, 262 while monitoring cellular response using single-cell calcium 263 imaging. Astroglial cells, either HAs or CAs, independently 264 cultured in chamber A of open oMFNs, were then primed with 265 $A\beta$ + IL-1 β for 24 h, washed, and further cultured for 6 h 266 (Figure 4a). Subsequently, the chambers were put into 267 f4 microfluidic communication using the closed microfluidic 268 setting, and intracellular calcium dynamics of HNs in chamber 269 2 were acquired by time-lapse ratiometric single-cell calcium 270 imaging acquisitions (Figure 4b). A quantitative analysis of the 271 response of HNs to either HA postpriming medium (PPh) or 272 CA postpriming medium (PPc) was then carried out. Figure 4c

274 shows that HNs challenged with PPh exhibit higher calcium 275 transients compared to HNs exposed to PPc. Neurons in both 276 chambers show higher basal intracellular calcium levels when in 277 microfluidic communication (Figure 4c, lower panel), but 278 respond similarly to 50 mM KCl stimulation, thus excluding a 279 different intrinsic neuronal responsiveness to depolarization 280 (Figure 4c, upper panel). In both cases, the calcium elevation 281 produced by the postpriming solution was blocked by the 282 NMDA receptor blocker APV (Figure 4b).

DISCUSSION

The analytical method shown here uses microfluidic networks in open and closed configurations to investigate the role played by astrocytes derived from different regions of the brain in controlling neuronal viability under two types of insults, ischemic insult and exposure to $A\beta$ + IL-1 β . In both situations, as a clear difference was found between hippocampal and cortical astrocytes, with hippocampal astrocytes failing in supporting neurons after ischemic insult and playing a more detrimental role on neurons after exposure to $A\beta$ + IL-1 β .

Although astrocytes throughout the central nervous system share many common traits, a marked phenotypic diversity is detectable among astrocytes from different brain regions. 19 Heterogeneity includes the different types and levels of neuropeptides and receptors and the specific expression of membrane transporters and channels. These phenotypic differences result in functional heterogeneity among cortical and hippocampal astrocytes which results in specific functional features, 77–29 for example, in an increased glutamate uptake capability by cortical rather than hippocampal astrocytes following injury. 19,30–32

Although ample data suggest that astrocytes play a role in 305 both the initiation and propagation of ischemic injury, the 306 contribution of specific astrocyte populations to this process 307 has never been defined. Astrocytes are the principal house-308 keeping cells of the nervous system, playing multiple supportive 309 tasks for neurons, including reuptake of neurotransmitters 310 released during synaptic activity, control of ion homeostasis and 311 release of neurotrophic factors, shuttling of metabolites and 312 waste products, and participation in the formation of the 313 blood-brain barrier.³³ Failure of any of these supportive 314 functions of astrocytes can represent a threat for neuronal 315 survival.³⁴ Evidence is suggesting that astrocytes and factors 316 released by astrocytes are differently modulating neuronal 317 functionality according to regional localization and concen-318 tration of chemical mediators. ¹⁷ In particular, it has been shown 319 that hippocampal astrocytes are more sensitive than cortical 320 astrocytes to OGD stimulation, resulting in an increased hippocampal release of LDH, although reasons for the observed 322 difference have to date not been determined.²⁰ By indicating a 323 selective neuroprotective action of CAs—but not of HAs— 324 upon OGD challenge, our data suggest regional differences in 325 astrocyte ability to support neuronal metabolic needs under 326 ischemic insult. This is likely to result from different astroglial suffering of CAs³⁵ and a higher sensibility of HAs to reactive oxygen species.³⁶ 327 vulnerability to ischemia, due to both a minor metabolic

A primary role of astrocytes in control of neuronal viability has also been demonstrated in neurodegenerative disorders, such as Alzheimer's disease (AD), in which neuroinflammatory events are heavily involved. The main inflammatory players in AD are the glial cells which initiate the inflammatory response. Indeed one of the earliest neuropathological changes in AD is

the accumulation of astrocytes at sites of $A\beta$ deposition. Several 336 lines of evidence suggest that neurons are damaged by 337 neurotoxic molecules elaborated from glial activation, and 338 indeed $A\beta$ induces inflammatory mediators, such as cyclo- 339 oxygenase 2 (COX-2), inducible nitric oxide synthase (iNOS), 340 IL-1 β , and tumor necrosis factor α . 37-45

Our data indicate that astrocytes from different brain regions 342 differently affect neuronal viability upon exposure to inflam- 343 matory stimulus $A\beta$ + IL-1 β , with HAs contributing more 344 heavily to neuronal death than CAs. The harmful effect of HAs 345 could presumably be mediated by the higher levels of glutamate 346 accumulated in the hippocampal relative to cortical astrocyte 347 medium upon stimulus challenge, given that neuronal death is 348 prevented by the NMDA blocker APV. However, it is very 349 likely that also other inflammatory mediators contribute to the 350 process.

352

369

CONCLUDING REMARKS

Dissecting the interactions between cell populations using a 353 flexible microfluidic format and various signal readouts is a 354 powerful method for investigating the specific dynamics of 355 molecular mechanisms involved in the crosstalk among 356 different cell populations during neuroinflammatory events. 357 By the combined action of morphological and functional 358 analysis on primary cell cultures, either cultured independently 359 or in microfluidic communication, we were able to distinguish 360 brain-region-specific glial contribution in two different in vitro 361 models of neuroinflammation, presumably because of a 362 glutamate-mediated excitoxicity caused by a region-dependent 363 alteration of metabolic activity. We suggest oMFNs and the 364 method shown here to be a valuable, versatile, and flexible 365 analytical solution to unravel how different cell types of the 366 brain contribute to the crosstalk events leading to neuro- 367 degeneration.

MATERIALS AND METHODS

oMFNs Fabrication and Setup. oMFNs were fabricated 370 by casting PDMS (Sylgard 184, Dow Corning, Midland, MI) 371 onto microstructured 4 in. Si wafers (Siltronix, Geneva, 372 Switzerland) used as molds. These Si molds were made using 373 standard photolithography (64 000 dpi polymer masks, 374 Zitzmann GmbH, Germany) and deep reactive ion etching 375 (STS ICP, Surface Technology Systems, U.K.). The Si molds 376 were coated with a fluorinated material (1H,1H,2H,2H-377 perfluorodecyltrichlorosilane from ABCR GmbH, Karlsruhe) 378 at the end of the etching process for better release of the PDMS 379 after curing overnight at 60 °C. To this end, the Si molds were 380 cleaned using an oxygen-based plasma, exposed to vapors of the 381 fluorinated silane using a desiccator (50-100 mbar and 30 min 382 of exposure time), and baked 2 h at 80 °C. The PDMS oMFNs 383 with 150 μ m deep structures were separated using a scalpel and 384 stored in a plastic dish until used.

The Si lids were fabricated using similar lithography and 386 etching processes as for the Si molds. NanoPort assemblies 387 (Upchurch Scientific, Ercatech, Switzerland) were mounted to 388 the backside of the lids, in alignment with the vias for liquid 389 connection.

Prior to the seeding of cells, the oMFNs were treated with an 391 oxygen-based plasma for 30 s (Technics Plasma 100 -E, 392 Florence, KY) at 200 W of coil power and then coated with 393 a $^{0.5}$ mg mL $^{-1}$ solution of poly-L-lysine. The oMFNs were 394 incubated with the poly-L-lysine overnight at room temper- 395

396 ature. After a washing step with PBS and water, the oMFNs 397 were dried under a stream of N_2 , and cell suspensions were 398 added onto the chambers. This was done by placing \sim 750 cells 399 mm⁻² in each chamber of an oMFN. The oMFN was then 400 placed in a Petri dish with a few milliliters of water next to it to 401 prevent evaporation of the liquid in the cell chambers. The 402 Petri dish with the oMFN was then kept in an incubator for up 403 to 10 days. If necessary, a replacement of growth medium 404 during incubation was done using a pipet.

The tubing and fittings needed for microfluidic experiments were purchased from Upchurch Scientific. Active pumping of liquids was done using high-precision syringe pumps (Cetoni GmbH, Korbussen, Germany), which were equipped with 50 μ L glass syringes (Hamilton, Bonaduz, Switzerland). A custom-made aluminum holder facilitated the assembly of the oMFN with the lid. During this procedure, the lid was normally connected to prefilled tubing to prevent air bubble formation in closed oMFNs.

Chemicals and Biomolecules. Antibodies against β III tubulin (cat. no. G712A, 1:300 dilution) were from Promega (Milano, Italy). A β_{1-42} (cat. no. 24224, 1 μ M) was from Anaspect (Fremont, CA); DAPI and Fura-2 AM were from Invitrogen (Milano, Italy). Propidium iodide (20 ng mL⁻¹), Abs against GFAP (1:100 dilution) and IB4 (1:200 dilution), and KCl were purchased from Sigma-Aldrich (Milano, Italy); IL-1 β was from Peprotech (DBA, Italy), and APV was from Tocris (Bristol, U.K.). Vglut (cat. no. 135311, 1:1000 dilution) was purchased from Synaptic Systems (Goettingen, Germany).

Primary Cultures of Hippocampal/Cortical Neurons 425 and Astrocytes. Primary neuronal cultures were prepared 426 from the brains of 18 day old rat embryos (Charles River, 427 Milan, Italy) as previously described³ with minor modifications. 428 Briefly, the hippocampi or cortices were isolated from total brain, incubated with trypsin at 37 °C, and then dissociated to obtain separated cells, which were then plated at a density of \sim 750 cells mm⁻² in each chamber of the chip and grown in 432 neurobasal medium supplemented with B27, 0.5 mM glutamine, and 12.5 μM glutamate. Hippocampal/cortical 434 astrocytic cultures from rat pups (P2) were obtained using 435 previously described methods. ³ Briefly, after dissection, the 436 hippocampi/cortices were dissociated by treatment with trypsin 437 (0.25% for 10 min at 37 °C) followed by fragmentation with a 438 fire-polished Pasteur pipet. The dissociated cells were cultured 439 for 14 days, trypsinized, and plated in a cell chamber at a 440 density of 2000 cells/chamber, and the cultures were grown in 441 minimum essential medium (Invitrogen, Italy) supplemented 442 with 20% fetal bovine serum (Euroclone Ltd., U.K.) and 443 glucose at a final concentration of 5.5 g $\rm L^{-1}$. Prior to 444 trypsinization, astrocytes were shaken as previously described³ 445 in order to detach microglia cells. Cell purity of astrocytic 446 culture on PDMS was confirmed by positivity to immunocy-447 tochemical staining with glial fibrillar acidic protein GFAP and lack of signal to microglia marker IB4 as previously reported. 16

Immunocytochemical Staining. Primary cells, both neurons and astrocytes, were fixed in 4% paraformaldehyde and 4% sucrose at room temperature (RT) for 10 min. Primary and secondary antibodies were applied in GDB buffer (30 mM phosphate buffer, pH 7.4, containing 0.2% gelatin, 0.5% Triton X-100, and 0.8 M NaCl) for 2 h at RT or overnight at 4 °C. The confocal images were acquired with a Leica SPE confocal microscope, using a Nikon (Tokyo, Japan) 40× objective. Each image was a z-series projection taken at 0.8 μm depth intervals.

Preparation of Fibrillar $A\beta$ and Cells Treatment. 458 Fibrillar $A\beta_{1-42}$ was prepared as previously described³⁰ by 459 incubating freshly solubilized peptides at 50 μ M in sterile water 460 for 5 days at 37 °C. CAs and HAs were stimulated with fibrillar 461 $A\beta_{1-42}$ (1 μ M) alone or combined to IL-1 β (10 nM). After 24 462 h, the cells were washed with Krebs–Ringer solution, fresh 463 neuronal medium was added, and the cells were placed in 464 coculture with HNs for 6 h.

OGD Protocol. To mimic ischemic condition in vitro, cells 466 were exposed to OGD following published methods. 44,45 467 Culture medium was replaced with a solution containing 130 468 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 1.2 mM MgSO₄, 1.2 mM 469 KH₂PO₄, and 25 mM 4-(2-hydroxyethyl)piperazine-1-ethane- 470 sulfonic acid (HEPES). Culture plates were placed in an airtight 471 chamber (Billups-Rothenberg, Del Mar, CA, U.S.A.). The 472 chamber was flushed with 95% N₂/5% CO₂ for 5 min with 20 L 473 min⁻¹ gas flow, sealed, and placed in a 37 °C incubator for the 474 appropriate duration. After the insult, OGD media were 475 replaced with neuronal complete medium, and the cultures 476 were returned to a normoxic environment. To examine the 477 effects of reperfusion, cells were analyzed either immediately or 478 after 24 h of recovery.

Quantitative Evaluation of Intracellular Calcium 480 **Dynamics.** Cultures were loaded for 35-40 min at 37 °C 481 with 2 µM Fura-2 AM in Krebs-Ringer solution buffered with 482 HEPES, 125 mM NaCl, 5 mM KCl, 1.2 mM MgSO₄, 2 mM 483 CaCl₂, 10 mM glucose, and 25 mM HEPES (pH 7.4) and were 484 washed twice with prewarmed Krebs-Ringer solution before 485 recordings were made. The recording setup comprised an 486 inverted microscope (Axiovert 100, Zeiss, Germany) equipped 487 with a Ca²⁺ imaging unit. Polychrome IV (TILL Photonics, 488 Germany) was used as a light source. Fura-2 fluorescence 489 images were collected with a PCO Super VGA SensiCam 490 (Axon Instruments, CA, U.S.A.) at 25 °C and analyzed with 491 TILL Vision Software (TILL Photonics, Germany). Single-cell 492 340/380 nm fluorescence ratios, acquired at a sampling 493 frequency of $1-4 \text{ s}^{-1}$, were analyzed with Origin 6.0 (Microcal 494 Software Inc., MA, U.S.A.).

Electrophysiological Recordings. Whole-cell voltage- 496 clamp recordings of spontaneous synaptic activity were 497 performed on rat embryonic HNs maintained in culture for 498 10–14 DIV. Patch pipettes (2–4 M Ω) were pulled using a 499 micropipet electrode puller (Sutter Instruments) and filled with 500 internal recording solution containing (in mM) KGluc 130, 501 EGTA 1, KCl 10, MgCl₂ 2, HEPES 10, Mg ATP 40, Tris-GTP 502 3 (pH 7.3). The cells plated on glass coverslips or in cell 503 chambers of microfluidic chips were placed in a recording 504 chamber perfused continuously with extracellular solution 505 containing (in mM) NaCl 125, KCl 5, MgSO₄ 1.2, CaCl₂ 2, 506 KHPO₄ 1.2, HEPES 25, Glu 6 (pH 7.3). Recordings were 507 conducted at -70 mV. The series resistance ranged from 10 to 50820 M Ω and was monitored for consistency during recordings. 509 Cells in culture with leak currents >100 pA were excluded from 510 our analysis. Signals were recorded using Multiclamp 700B 511 amplifiers and digitized with Digidata 1440 (Axon Instruments, 512 Molecular Devices). Signals were amplified, sampled at 10 kHz, 513 filtered to 2 or 5 kHz, and analyzed using the pClamp 10 data 514 acquisition and analysis program.

Data Analysis. The data are presented as means \pm SE. 516 Statistical significance was evaluated by the Student's t test or 517 one-way ANOVA. Differences were considered significant if p = 518 0.05 and are indicated by an asterisk in all figures, whereas 519 those at p < 0.01 are indicated by double asterisks.

521 AUTHOR INFORMATION

522 Corresponding Author

*Phone: +39-02-56660156. E-mail: fabio.bianco@neuro-zone.

525 Author Contributions

526 [¶]These authors contributed equally to this work.

528 The authors declare the following competing financial 529 interest(s): the publication can have an impact on the group's 530 rating in the companies at the end of the year. This can 531 influence salaries (bonus, salary increase etc.).

ACKNOWLEDGMENTS

533 We thank R. Stutz for his help with the fabrication of molds and 534 chips, M. Hitzbleck, G. V. Kaigala, and C. Verderio for 535 discussions, and W. Riess, M. Despont, and V. Vogel (ETHZ) 536 for their continuous support. This work was partially supported 537 by MIUR art. 11 D.M. no. 593/2000 to M.M. and F.B., by 538 CARIPLO 2008-3184 to M.M., and by the European Union 539 Seventh Framework Program under Grant Agreement No. 540 HEALTH-F2-2009-241498 ("EUROSPIN" project) to M.M.

REFERENCES

- (1) Golde, T. E. Mol. Neurodegener. 2009, 4, 4-8. 542
- (2) Glass, C. K.; Saijo, K.; Winner, B.; Marchetto, M. C.; Gage, F. H. 543 544 Cell 2012, 19, 918-934.
- (3) Bianco, F.; Pravettoni, E.; Colombo, A.; Schenk, U.; Moller, T.;
- 546 Matteoli, M.; Verderio, C. J. Immunol. 2005, 174, 7268-7277.
- (4) Agostinho, P.; Cunha, R. A.; Oliveira, C. Curr. Pharm. Des. 2010, 547 548 16, 2766-2778.
- 549 (5) Salmina, A. B. J. Alzheimer's Dis. 2009, 16, 485-502.
- (6) El-Ali, J.; Sorger, P. K.; Jensen, K. F. Nature 2006, 27, 403-411. 550
- (7) Cooksey, G. A.; Sip, C. G.; Folch, A. Lab Chip 2009, 9, 417–426. 551
- (8) Nilsson, J.; Evander, M.; Hammarström, B.; Laurell, T. Anal. 553 Chim. Acta 2009, 649, 141-157.
- (9) Lovchik, R. D.; Bianco, F.; Matteoli, M.; Delamarche, E Lab Chip 554 555 2009, 9, 1395-1402.
- (10) Taylor, A. M.; Rhee, S. W.; Tu, C. H.; Cribbs, D. H.; Cotman, 557 C. W.; Jeon, N. J. Langmuir 2003, 19, 1551-1556.
- (11) Futai, N.; Gu, W.; Song, J. W.; Takayama, S. Lab Chip 2006, 6, 558 559 149-154.
- (12) Lovchik, R. D.; Bianco, F.; Tonna, N.; Ruiz, A.; Matteoli, M.; 561 Delamarche, E. Anal. Chem. 2010, 82, 3936-3942.
- (13) Hsu, C.-H.; Chen, C.; Folch, A. Lab Chip 2004, 4, 420-424. 562
- (14) Sung, J. H.; Kam, C.; Shuler, M. L. Lab Chip 2012, 10, 446-563 564 455
- (15) Wu, H.-I.; Cheng, G.-H.; Wong, Y.-Y.; Lin, C.-M.; Fang, W.; 565 566 Chow, W.-Y.; Chang, Y.-C. Lab Chip 2010, 10, 647-653.
- (16) Lovchik, R. D.; Tonna, N.; Bianco, F.; Matteoli, M.; 567 568 Delamarche, E. Biomed. Microdevices 2010, 12, 275-282.
- (17) Lin, C. H.; Chen, P. S.; Gean, P. W. Eur. J. Pharmacol. 2008, 569 570 589, 85-93.
- (18) Tan, J.; Town, T.; Saxe, M.; Paris, D.; Wu, Y.; Mullan, M. J. 571 572 Immunol. 1999, 163, 6614-6621.
- (19) Han, B. C.; Koh, S. B.; Lee, E. Y.; Seong, Y. H. Life Sci. 2004, 76, 574 573-583.
- (20) Lee, Y. S.; Ouyang, Y. B.; Giffard, R. G. FEBS Lett. 2006, 580, 575 576 4865-4871.
- (21) Venance, L.; Prémont, J.; Glowinski, J.; Giaume, C. J. Physiol. 577 578 **1998**, 510, 429-440.
- (22) McCarthy, K. D.; Salm, A. K. Neuroscience 1991, 41, 325-333.
- (23) Sharif, A.; Duhem-Tonnelle, V.; Allet, C.; Baroncini, M.;
- 581 Loyens, A.; Kerr-Conte, J.; Collier, F.; Blond, S.; Ojeda, S. R.; Junier, 582 M. P.; Prevot, V. Glia 2009, 57, 362-379.
- 583 (24) Shinoda, H.; Marini, A. M.; Cosi, C.; Schwartz, J. P. Science 584 **1989**, 245, 415-417.

- (25) Olsen, M. L.; Campbell, S. L.; Sontheimer, H. J. Neurophysiol. 585 2007, 98, 786-793.
- (26) Oberheim, N. A.; Goldman, S. A.; Nedergaard, M. Methods Mol. 587 Biol. 2012, 814, 23-45.
- (27) McKhann, G. M.; D'Ambrosio, R.; Janigro, D. J. Neurosci. 1997, 589 17, 6850-6863.
- (28) Matthias, K.; Kirchhoff, F.; Seifert, G.; Hüttmann, K.; Matyash, 591 M.; Kettenmann, H.; Steinhäuser, C. J. Neurosci. 2003, 23, 1750-1758. 592
- (29) Poopalasundaram, S.; Knott, C.; Shamotienko, O. G.; Foran, P. 593 G.; Dolly, J. O.; Ghiani, C. A.; Gallo, V.; Wilkin, G. P.; Ralay Ranaivo, 594 H.; Craft, J. M.; Hu, W.; Guo, L.; Wing, L. K.; Van Eldik, L. J.; 595 Watterson, D. M. J. Neurosci. 2006, 26, 662-670.
- (30) Morga, E.; Faber, C.; Heuschling, P. J. Neuroimmunol. 1998, 87, 597 179 - 184598
- (31) Kipp, M.; Norkute, A.; Johann, S.; Lorenz, L.; Braun, A.; Hieble, 599 A.; Gingele, S.; Pott, F.; Richter, J.; Beyer, C. J. Mol. Neurosci. 2008, 35, 600
- (32) Fitting, S.; Zou, S.; Chen, W.; Vo, P.; Hauser, K. F.; Knapp, P. E. 602 J. Proteome Res. 2010, 9, 1795-1804.
- (33) Volterra, A.; Meldolesi, J. Nat. Rev. Neurosci. 2005, 6, 626-640. 604
- (34) Takano, T.; Oberheim, N.; Cotrina, M. L.; Nedergaard, M. 605 Stroke 2009, 40, 8-12. 606

607

- (35) Zhao, G.; Flavin, M. P. Neurosci. Lett. 2000, 285, 177-180.
- (36) Silva, G. A.; Feeney, C.; Mills, L. R.; Theriault, E. Eur. J. 608 Neurosci. Methods 1998, 80, 75-79.
- (37) Valles, S. L.; Dolz-Gaiton, P.; Gambini, J.; Borras, C.; Lloret, A.; 610 Pallardo, F. V.; Viña, J. Brain Res. 2010, 1312, 138-144. 611
- (38) Meda, L.; Cassatella, M. A.; Szendrei, G. I.; Otvos, L.; Baron, P.; 612 Villalba, M.; Ferrari, D.; Rossi, F. Nature 1995, 374, 647-650.
- (39) Tan, K. H.; Purcell, W. M.; Heales, S. J.; McLeod, J. D.; Hurst, 614 R. D. NeuroReport 2002, 13, 2587-2591. 615
- (40) Jana, A.; Pahan, K. J. Neurosci. 2010, 30, 12676-12689.
- (41) Ralay Ranaivo, H.; Craft, J. M.; Hu, W.; Guo, L.; Wing, L. K.; 617 Van Eldik, L. J.; Watterson, D. M. J. Neurosci. 2006, 26, 662-670. 618
- (42) Brewer, G. J.; Torricelli, J. R.; Evege, E. K.; Price, P. J. J. 619 Neurosci. Res. 1993, 35, 567-576.
- (43) Calegari, F.; Coco, S.; Taverna, E.; Bassetti, M.; Verderio, C.; 621 Corradi, N.; Matteoli, M.; Rosa, P. J. Biol. Chem. 1999, 274, 22539-622
- (44) Romera, C.; Hurtado, O.; Botella, S. H.; Lizasoain, I.; Cárdenas, 624 A.; Fernández-Tomé, P.; Leza, J. C.; Lorenzo, P.; Moro, M. A. J. 625 Neurosci. 2004, 24, 1350-1357. 62.6
- (45) Goldberg, M. P.; Choi, D. W. J. Neurosci. 1993, 13, 3510-3524. 627